Food supplement Sivomixx®800 reduces mortality of hospitalized COVID-19 patients

01 April 2021 | News

Next Gen Pharma announces the positive outcome, now published in Frontiers in Nutrition, of an Italian retrospective clinical study

New Delhi based Next Gen Pharma India, a subsidiary of Ormendes SA, Switzerland, has announced the positive outcome, now published in Frontiers in Nutrition, of an Italian retrospective clinical study confirming reduced mortality of hospitalized COVID-19 patients with severe pneumonia when supplemented with Sivomixx®800. 

The clinical study has confirmed the possible role of the probiotic product Sivomixx®800 as a supplement to hospitalized Covid-19 patients who are also receiving standard care.

In a prior study, published late last year, patients administered the same Pro-Biotherapeutic in the intensive care unit (ICU) setting was less likely to be subject to incubation and had reduced levels of diarrhoea. 

In the last study, 70 Covid-19 patients with lung involvement, for whom non-invasive oxygen therapy treatment was requested, were recruited and divided into two groups: one of 42 patients and the other one of 28.

Both groups received a treatment based on hydroxychloroquine, antibiotics, and/or tocilizumab, whereas only the 28 patients in the second group concomitantly received Sivomixx®800.

Interestingly, nearly all patients treated with bacteriotherapy/Pro-Biotherapeutic showed a reduction of diarrhoea and improvement in fever, physical weakness, and myalgia within 5-7 days.

The patients receiving Pro-Biotherapeutic/oral bacteriotherapy all survived the COVID-19 disease and none required invasive mechanical ventilation. Their estimated risk of developing respiratory failure was eight-fold lower compared to the non-supplemented group.

Speaking on the successful clinical trials, Kanwaldeep Singh Chadha, CEO of Next Gen Pharma, said, “In spite of strategies like social distancing, frequent sanitization, and screening, COVID-19 is spreading intensely throughout the world, with healthcare systems at risk of being overpowered. While transmission of SARS-CoV-2 is assumed to occur mainly through respiratory drops, the gut may also contribute toward the pathogenesis of the virus. Usage of probiotic strains identified for anti-viral and respiratory activities should become part of the armamentarium to reduce the intensity of this pandemic.”


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

© Copyright 2021. Nuffoods Spectrum. All Rights Reserved.
Website Design & Developed By : SCI Knowledge Interlinks